secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001493152-24-024720
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals acquires three ANDAs from Nostrum Laboratories for $900k
------------------------------------------------------------------------------

- Acquired ANDAs for generic Norco (hydrocodone/APAP), Percocet (oxycodone/APAP), and Dolophine (methadone) from Nostrum.
- Paid $900,000 cash; also received royalty-free perpetual license for manufacturing technology.
- Asset Purchase Agreement signed June 17, 2024; transaction closed June 21, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224024720/0001493152-24-024720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224024720/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-024720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer